Intelligent Bio Solutions Announces Completion of Multi-Site Study for Codeine Test

What Happened Intelligent Bio Solutions Inc. (INBS) announced on August 11, 2026 (via a press release furnished on Form 8-K) that it completed a multi-site Method Comparison Study for its Intelligent Fingerprinting Drug Screening System. The company says this study is one of several that underpin its FDA 510(k) submission seeking U.S. market clearance for detection of the opiate codeine. The disclosure was made pursuant to Regulation FD and the press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Date of disclosure: August 11, 2026 (press release furnished on Form 8-K).
• Product: Intelligent Fingerprinting Drug Screening System.
• Study: Completed multi-site Method Comparison Study focused on detection of the opiate codeine.
• Regulatory context: Study supports the company’s FDA 510(k) submission for U.S. market clearance; press release is Exhibit 99.1.

Why It Matters This is a regulatory milestone: completing a multi-site comparison study is a concrete step in the 510(k) process that could help the company obtain U.S. market clearance for codeine detection if the submission and review are successful. For investors, the item signals progress on product validation and the regulatory pathway but does not guarantee clearance, revenue, or timing — the filing contains no financial results or timeline updates.